Propofol Sedation for Patients Undergoing Gastrointestinal Endoscopy Procedures: Challenging Existing Paradigms in Healthcare

Davinder Garewal

Department of Anaesthesia, St George’s Hospital, Blackshaw Rd, London SW17 0QT, United Kingdom

*Corresponding author: Davinder Garewal, Consultant Anaesthetist, Department of Anaesthesia, St George’s Hospital, Blackshaw Rd, London SW17 0QT, United Kingdom; E-mail: acba5e@r.postjobfree.com

Received date: Apr 22, 2014, Accepted date: July 28, 2014, Published date: August 05, 2014

Copyright: © 2014 Garewal G. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Introduction

Born an anaesthetic, propofol has in recent years re-emerged as its alter ego, a pre- eminent sedative agent. In this capacity, propofol is significantly superior to traditional sedative agents for patients undergoing gastrointestinal endoscopy procedures. A key advantage is that patients recover better after propofol sedation than conventional (benzodiazepine/opioid) sedation [1,2]. It is ironic that noteworthy research in this area has been conducted by gastroenterologists, for they are not licensed to administer propofol to patients. Propofol is considered by many to now be the preferred sedative drug for patients undergoing gastrointestinal endoscopy procedures. The worldwide demand for optimal sedation in patients undergoing endoscopy procedures is vast, and will likely multiply with increasing awareness of the advantages of propofol sedation, and a growing elderly population [3]. However, it must be born in mind that propofol was initially introduced as an anaesthetic agent, and has potent cardio- respiratory depressant properties [4]. Propofol therefore has the potential to cause apnoea, respiratory obstruction and hypotension when administered to patients as a sedative agent. Current U.S. Food and Drug Administration (FDA) regulations state that administration of propofol to patients should only be performed by trained anaesthesia personnel. This limits the availability of propofol sedation to many patients undergoing gastrointestinal endoscopic procedures.

The demand for propofol sedation has created discord between gastroenterologists and anaesthesiologists. Gastroenterologists in North America have asserted that they can administer propofol safely to patients undergoing endoscopic procedures, and in the USA have petitioned the FDA to be able to do so [4-6]. However anaesthesiologists have opposed their attempts, and the FDA rejected their proposal in 2010. It is not surprising that there are divergent opinions between the specialties in this shared territory of sedation practice. However, it is possible that both sides have valid points to present.

In an endeavor to gain a deeper insight into this conflict, one could reflect on whether the phenomenon of the “Rashamon effect” [7] has any validity here [7]. The “Rashamon effect” is a concept illustrated in the classic Kurosawa film Rashamon. In the film, different people with different backgrounds provide alternative, self-serving and contradictory versions of the same incident. If we were to analyse the propofol sedation question with a medical “Rashamon” lens, could we arrive at a more patient focused solution than that currently available?

The Merits of Propofol Sedation

Propofol sedation is clearly more effective, and associated with better recovery and shorter discharge periods than conventional sedation, in patients undergoing gastrointestinal endoscopy procedures [1,2]. Not only is immediate recovery faster and better, but the recovery profile 24 hours after the procedure is improved following propofol sedation [8]. In addition, it has been argued that propofol sedation is safer than the traditional sedative technique [9]. This is powerful evidence supporting this form of sedation.

Gastroenterology Perspective

Gastroenterologists can rightly claim to be experts in the field of sedation. Historically they have been the main providers of this service to patients undergoing gastrointestinal endoscopy procedures. The traditional sedative technique has been to administer midazolam or benzodiazepine, either on its own or in combination with an opioid, to target conscious sedation in patients undergoing these procedures. It is of note that deep sedation has been shown to be a frequent result of this technique [10], so gastroenterologists are no strangers to dealing with heavily sedated patients. In more recent years gastroenterologists have been instrumental in demonstrating the superiority of propofol sedation over conventional sedation in patients undergoing gastrointestinal endoscopy procedures [1,2]. Furthermore, Rex and colleagues have presented data from a worldwide safety survey to support the notion that endoscopist directed propofol sedation is safe, and probably safer than conventional sedation [9]. The argument for endoscopist directed propofol sedation is further strengthened if one considers the relatively high cost of anaesthesia administered propofol sedation.

Concerns of Anaesthetists and Anesthesiologists

Anaesthesia specialists have concerns regarding non-anaesthesia personnel administered propofol sedation for several reasons.

Propofol has the potential to cause rapid and profound changes in sedative/anaesthetic depth, it has no specific antidotes and can demonstrate marked synergy with other drugs [11]. Although conscious sedation may be targeted in patients, deep sedation may be necessary for more uncomfortable gastrointestinal procedures, or may result due to variability in patient’s sensitivity to propofol. There is therefore a significant risk of respiratory compromise occurring in patients receiving propofol sedation, a complication that requires swift intervention. In addition, the shared and open airway in patients undergoing gastrointestinal endoscopy procedures under sedation poses further potential hazards of regurgitation and aspiration. Although this risk is relatively rare, as patients are routinely fasted prior to the procedures, it is an ever present and sometimes unpredictable occurrence [12], and requires immediate action. Not surprisingly, anaesthesia personnel feel that they are the most suitable medical professionals to deal with the above mentioned complications.
In consideration of the potential hazards of propofol sedation in patients undergoing gastrointestinal endoscopy procedures, some anaesthesia practitioners consider traditional general anaesthesia with tracheal intubation to be a more reliable and safer technique in patients undergoing these procedures [13].

Deep sedation is a level of sedation described in the American Society of Anesthesiologists (ASA) classification of sedative levels [14]. It has been defined as “A drug-induced depression of consciousness during which the patient cannot be easily aroused, but responds purposefully following repeated or painful stimulation, and during which independent ventilatory function may be impaired”. This category of sedation has created further misunderstanding in the ongoing debate around propofol sedation. Although the gastroenterology community may be right to point out that deep sedation is not categorised as general anaesthesia by the ASA classification, many anaesthesiologists regard deep sedation as indistinguishable from light general anaesthesia. They are therefore uncomfortable with the idea of non-anaesthesia personnel independently administering propofol to patients.

Do we have enough evidence about the safety profile of propofol sedation? In contrast to the data presented by Rex and colleagues [9], the ASA closed claims database suggests that propofol sedation is not without problems [15]. Metzner analysed remote location claims for injuries in this database, and found propofol (as a sedative agent) to be the commonest drug administered to patients in these instances. The gastrointestinal suite was responsible for 32% of remote location claims, and respiratory depression due to overdose of sedative-hypnotic-analgesic drugs accounted for more than half the claims in the gastrointestinal suite. Finally, the severity of patient injury in remote location claims was far greater than that of operating room claims, with the proportion of death almost double in the remote injury claims [15]. Further data relating to the safety of propofol sedation may well become available with the passage of time.

Conclusion

What conclusion can we draw from these conflicting findings and opinions? It seems that propofol is a novel sedative whose use requires a new paradigm of sedative care. It can often be administered safely to patients by non-anaesthesia personnel, but whenever complications such as respiratory compromise and significant regurgitation occur, immediate assistance by anaesthesia personnel is desirable.

One solution would be to incorporate an anesthesiologist/anaesthetist into the endoscopy team in hospitals. Anaesthesia presence in the endoscopy suite could ensure that patients unsuitable for propofol sedation are identified and undergo their procedure under standard general anaesthesia with tracheal intubation. The remainder of patients could receive propofol sedation for their procedures, administered by appropriately trained non-anaesthesia personnel, and supervised by the anaesthetist/anaesthesiologist (provided of course that the relevant licensing bodies are in agreement). As the anaesthesia specialist would be attendant in the gastroenterology suite for the duration of the scheduled endoscopy procedures, immediate assistance would be available in case of mishaps.

Future developments may result in newer drugs and safer techniques becoming available for use in this important and expanding area of medical practice. However, for progress in patient care to be realised, it may also be necessary for physicians across specialties to engage with each other and reassess traditional models of care.

References

1. Garewal D, Powell S, Milan SJ, Nordmeyer J, Waikar P (2012) Sedative techniques for endoscopic retrograde cholangiopancreatography. See comment in PubMed Commons below Cochrane Database Syst Rev 6: CD007274.
2. Wang D, Chen C, Chen J, Xu Y, Wang L, et al. (2013) The use of propofol as a sedative agent in gastrointestinal endoscopy: a meta-analysis. See comment in PubMed Commons below Cochrane Database Syst Rev 6: CD007274.
3. Peery AF, Dellon ES, Lund J, Crockett SD, Mc Gowan CE, et al. (2012) Burden of gastrointestinal disease in the United States: 2012 update. See comment in PubMed Commons below Gastroenterology 143: 1179-1187.
4. Department of Health and Human Services, “Petition denial for request for removal of warning of labeling for Diprivan (propofol)” Docket no FDA-2005-P-0059, August 2010.
5. Byrne MF, Chiba N, Singh H, Sadowski DC; Clinical Affairs Committee of the Canadian Association of Gastroenterology (2008) Propofol use for sedation during endoscopy in adults: a Canadian Association of Gastroenterology position statement. See comment in PubMed Commons below Can J Gastroenterol 22: 457-459.
6. Vargo JJ, Cohen LB, Rex DK, Kwo PY (2009) Position statement: Nonanesthesiologist administration of propofol for GI endoscopy. See comment in PubMed Commons below Am J Gastroenterol 104: 2886-2892.
7. http://en.wikipedia.org/wiki/Rashomon
8. Vargo JJ, Zuccaro G (Jr), Dumot JA, Shermock KM, Morrison JB, et al. (2002) Gastroenterologist-administered propofol versus midazolam/meperidine for advanced upper endoscopy: A prospective randomised trial. Gastroenterology 123: 8-16.
9. Rex DK, Deenadayalu VP, Eid E, Imperiale TF, Walker JA, et al. (2009) Endoscopist-directed administration of propofol: a worldwide safety experience. See comment in PubMed Commons below Gastroenterology 137: 1229-1237.
10. Patel S, Vargo JJ, Khandwala F, Lopez R, Trolli P, et al. (2005) Deep sedation occurs frequently during elective endoscopy with meperidine and midazolam. See comment in PubMed Commons below Am J Gastroenterol 100: 2689-2695.
11. The joint Royal Colleges of Anaesthetists (RCoA) and British Society of Gastroenterology (BSG) Working Party (2011), “Guidance for the use of propofol sedation for adult patients undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP) and other complex upper GI endoscopic procedures”.
12. ANZCA statement, “Anaesthesia/sedation for endoscopy. Beware unexpected aspiration”.
13. Garewal D, Vele L, Waikar P (2013) Anaesthetic considerations for endoscopic retrograde cholangio-pancreatography procedures. See comment in PubMed Commons below Curr Opin Anaesthesiol 26: 475-480.
14. ASA House of Delegates (1999) ”Continuum of depth of sedation, definition of general anaesthesia, and levels of sedation/analgesia” ASA standards, Guidelines and Statements.
15. Metzner J, Domino BD. Risk of anesthesia care in remote locations. Anesth Pat Saf Found 2011; 26: 5-7.